Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Sermonix Pharmaceuticals Inc. is a privately held biopharmaceutical company specializing in the development and commercialization of novel therapeutics for women's health, with a primary emphasis on treating endocrine-resistant metastatic breast cancer. Their lead investigational drug, lasofoxifene, is an oral, selective estrogen receptor modulator (SERM) being evaluated for its potential in treating ESR1-mutated metastatic breast cancer. Sermonix is dedicated to addressing significant unmet medical needs in women's oncology by advancing targeted therapies aimed at improving patient outcomes and quality of life.
Serves as the central hub for strategic decision-making, clinical development oversight, research initiatives, corporate administration, and business development activities.
Located in a modern office building within the Arena District, known for its vibrant business environment and accessibility.
A dynamic, science-driven, and patient-focused work environment. The culture likely emphasizes collaboration, innovation, and a strong commitment to advancing women's health.
The Columbus, Ohio location provides access to a growing life sciences ecosystem, research institutions, and a skilled talent pool, supporting the company's research and development efforts.
Sermonix Pharmaceuticals' global presence is primarily driven by its clinical trial operations and strategic partnerships. While headquartered in the U.S., the company conducts multinational clinical studies for lasofoxifene, involving research sites and investigators across North America, Europe, and potentially other regions. Their business development efforts also span globally as they seek collaborations and explore market access for their therapies.
394 W. Nationwide Blvd., Suite 200
Columbus
Ohio
USA
Address: Not Publicly Listed
If such presences exist, they would likely support geographically dispersed clinical trials, regulatory affairs, or business development in key markets.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Sermonix Pharmaceuticals' leadership includes:
Sermonix Pharmaceuticals has been backed by several prominent investors over the years, including:
Based on publicly available information in the last 12-18 months, Sermonix has maintained a stable core executive team with some strategic additions. For instance, Dr. Barry Komm was appointed CSO in late 2022, strengthening their scientific leadership.
Discover the tools Sermonix Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Sermonix Pharmaceuticals most commonly uses the email format of the employee's first initial followed by their last name. Other formats might be used less frequently.
flast@sermonix.com
Format
jdoe@sermonix.com
Example
80%
Success rate
GlobeNewswire • December 13, 2023
Sermonix Pharmaceuticals Inc. announced a strategic investment from the AMR Action Fund and an existing investor. The proceeds will be used to advance the clinical development of lasofoxifene, its lead investigational drug for ER+/HER2- metastatic breast cancer with an ESR1 mutation....more
Sermonix Pharmaceuticals (Press Release) • October 21, 2023
Sermonix presented updated, encouraging results from its ELAINE-1 and ELAINE-2 Phase 2 studies evaluating lasofoxifene in ER+/HER2- metastatic breast cancer patients with ESR1 mutations at the European Society for Medical Oncology (ESMO) Congress 2023....more
GlobeNewswire • September 27, 2023
Sermonix announced positive findings from a post-hoc analysis of the ELAINE-2 trial, showing lasofoxifene combined with abemaciclib demonstrated notable clinical benefit in heavily pre-treated ER+/HER2- metastatic breast cancer patients with ESR1 mutations....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Sermonix Pharmaceuticals, are just a search away.